Related Experiment Video

Updated: May 20, 2026

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

Antiangiogenic therapeutic approaches in multiple myeloma

Domenico Ribatti1, Giuseppe Mangialardi, Angelo Vacca

  • 1Department of Basic Medical Sciences, Section of Human Anatomy and Histology, University of Bari Medical School, Piazza Giulio Cesare, 11, Bari, Italy. ribatti@anatomia.uniba.it

Current Cancer Drug Targets
|July 12, 2012
PubMed

Insights

Angiogenesis, the growth of new blood vessels, drives multiple myeloma (MM) progression. Antiangiogenic therapies targeting this process show promise for MM treatment.

Area of Science:

  • Oncology
  • Hematology
  • Molecular Biology

Background:

  • Angiogenesis is a critical factor in multiple myeloma (MM) progression and impacts patient prognosis.
  • MM pathophysiology involves plasma cells producing angiogenic cytokines and influencing the bone marrow microenvironment.
  • Understanding angiogenesis-related signaling is key to developing effective anti-MM therapies.

Purpose of the Study:

  • To review the current literature on antiangiogenic therapies for multiple myeloma (MM).
  • To summarize the use of key antiangiogenic agents in preclinical and clinical MM settings.

Main Methods:

  • Comprehensive literature review of studies on angiogenesis in multiple myeloma.
  • Analysis of data on antiangiogenic therapeutic agents used in preclinical models and clinical trials for MM.

Main Results:

  • Angiogenesis is a consistent feature of MM, correlating with disease progression.
  • Multiple antiangiogenic agents are under investigation and in clinical use for MM.
  • The efficacy of these agents in preclinical and clinical settings is documented.

Conclusions:

  • Targeting angiogenesis is a validated therapeutic strategy in multiple myeloma.
  • Antiangiogenic therapies represent an important advancement in MM treatment.
  • Further research into novel antiangiogenic agents and combinations is warranted.

More Related Videos

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis10:04

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube (SWCNT)-delivered MALAT1 Antisense Oligos07:24

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube (SWCNT)-delivered MALAT1 Antisense Oligos

Published on: December 13, 2018

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...